Freedom of Information Request – Ref: FOI 236-2022
Thank you for your recent Freedom of Information request. Please find our response below:
I am requesting the following information on behalf of Novartis.
The purpose of these questions is to understand the variability of treatment within your trust and apply that to the context of the rest of the country.
Q1. How many patients has your trust treated for any disease. in the last 6 months or the latest 6 months data you have available. with the treatments listed below:
Revolade eltrombopag. zero
Nplate romiplostim. zero
Doptelet avatrombopag. zero
Tavlesse fostamatinib. zero
Q2. In the last 6 months or the latest 6 months data you have available., how many patients has your trust treated for immune thrombocytopenia ITP.? zero
Q3. Of the patients treated for immune thrombocytopenia ITP. in the last 6 months or the latest 6 months data you have available., how many were treated with: as answer to Q2
Rituximab mycophenolate mofetil
surgery splenectomy.
Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia ITP.? NO
If so, can you please provide the name of each trial along with the number of patients taking part?
FOI Request
I am requesting the following information on behalf of Novartis.
The purpose of these questions is to understand the variability of treatment within your trust and apply that to the context of the rest of the country.
Q1. How many patients has your trust treated for any disease. in the last 6 months or the latest 6 months data you have available. with the treatments listed below:
Revolade eltrombopag.
Nplate romiplostim.
Doptelet avatrombopag.
Tavlesse fostamatinib.
Q2. In the last 6 months or the latest 6 months data you have available., how many patients has your trust treated for immune thrombocytopenia ITP.?
Q3. Of the patients treated for immune thrombocytopenia ITP. in the last 6 months or the latest 6 months data you have available., how many were treated with:
rituximab
mycophenolate mofetil
surgery splenectomy.
Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia ITP.? If so, can you please provide the name of each trial along with the number of patients taking part?